E0 ConsensusModerate confidencePEM ?Machine draft
The European ME/CFS Biomarker Landscape project: an initiative of the European network EUROMENE.
Scheibenbogen, Carmen, Freitag, Helma, Blanco, Julià et al. · Journal of translational medicine · 2017 · DOI
Quick Summary
Researchers across Europe are working together to find biological markers (signs in blood or body tests) that could help diagnose ME/CFS and track how treatments work. This study reviewed all the biomarker research happening in Europe and created a database of what scientists are studying. The goal is to develop reliable tests that doctors could use in the future to diagnose ME/CFS and improve clinical trials.
Why It Matters
ME/CFS currently lacks validated diagnostic biomarkers and approved treatments, making diagnosis difficult and clinical trials hard to evaluate. This coordinated European effort to map and standardize biomarker research accelerates progress toward reliable diagnostic tests and better tools for measuring treatment response, which could transform how ME/CFS patients are identified and cared for.
Observed Findings
- - Multiple European research groups are actively investigating ME/CFS biomarkers across various biological systems
- - Significant gaps exist in standardized protocols for biomarker study design and reporting across European centers
- - There is substantial heterogeneity in patient populations and methodologies used in existing biomarker research
Inferred Conclusions
- - Coordinated, standardized approaches to biomarker development are essential for translating research findings into clinical tools
- - Improved cooperation and shared standards among European researchers can accelerate progress toward validated diagnostic and surrogate biomarkers
- - Establishing a centralized database facilitates identification of research gaps and opportunities for collaboration
Remaining Questions
- - Which biomarker candidates show the greatest promise for clinical diagnostic use?
- - What standardized protocols will best ensure reproducibility across different European research centers?
- - How can biomarker research be translated from discovery to validated clinical tests within realistic timeframes?
- - What is the optimal strategy for integrating multiple biomarkers into a composite diagnostic algorithm?
What This Study Does Not Prove
This study does not identify which specific biomarkers are definitively diagnostic or predictive—it maps the landscape of research rather than validating individual biomarkers. It does not prove that any particular biomarker is ready for clinical use; it lays groundwork for future validation studies.
Metadata
- DOI
- 10.1186/s12967-017-1263-z
- PMID
- 28747192
- Review status
- Machine draft
- Evidence level
- Established evidence from major reviews, guidelines, or evidence maps
- Last updated
- 8 April 2026